Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific, Medtronic Heart Devices Go To Panel In March

This article was originally published in The Gray Sheet

Executive Summary

FDA's Circulatory System Devices advisory panel will weigh in on two closely watched approval decisions at a March 18-19 meeting

You may also be interested in...



Medtronic Spine Sales Down In Fiscal Q3, But Firm Expects A Rebound In 2011

Medtronic is looking to turn around its flagging spine business by mid-2011, CEO Bill Hawkins said during the firm's Feb. 23 fiscal third quarter earnings call

Medtronic Spine Sales Down In Fiscal Q3, But Firm Expects A Rebound In 2011

Medtronic is looking to turn around its flagging spine business by mid-2011, CEO Bill Hawkins said during the firm's Feb. 23 fiscal third quarter earnings call

Boston Scientific CRM In 2010: Steep Challenges, Some Prospects

Sales force firings and perceived product design issues are adding to an already challenging cardiac rhythm management picture for Boston Scientific in 2010

Related Content

Topics

UsernamePublicRestriction

Register

MT028519

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel